Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | PLAU | P00749 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 7/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31429292 | 0.92 | ELANE (0.56) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL2808445 | 0.90 | ELANE (0.49) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL19675103 | 0.90 | CNR1 (0.47) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL3065175 | 0.89 | ELANE (0.50) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL15882396 | 0.89 | ELANE (0.58) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL15882017 | 0.88 | CNR1 (0.50) | CNR1CNR2CYP3A4KDM4CKDM4E | |
| SCHEMBL17324730 | 0.88 | CNR1 (0.48) | CNR1CNR2HTR4CYP3A4HTR3A | |
| SCHEMBL17287279 | 0.87 | CNR1 (0.60) | ELANEPLAUF2CNR1CNR2 | |
| SCHEMBL20250798 | 0.86 | CNR1 (0.49) | CNR1CNR2HTR4CYP3A4HTR3A | |
| SCHEMBL31429235 | 0.85 | ELANE (0.57) | ELANEPLAUF2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ELANE 557/4885PLAU 886/4885F2 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.